Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors - Trial NCT06352359
Access comprehensive clinical trial information for NCT06352359 through Pure Global AI's free database. This Phase 1 trial is sponsored by OncoC4, Inc. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
OncoC4, Inc.
Timeline & Enrollment
Phase 1
Jun 30, 2024
Jun 30, 2027
Primary Outcome
Dose Limiting Toxicity (DLT),Maximum Toxicity Dose (MTD)
Summary
This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841
 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate
 seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06352359
Non-Device Trial